MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

513.79 -7.49

Buy Sell

Overview

Share price change

24h

Current

Min

509.12

Max

556.51

Key metrics
By Trading Economics
Income	-72M -114M
Sales	74M 287M
Profit margin	-39.75
Employees	528
EBITDA	-68M -106M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+12.58% upside

Dividends
By Dow Jones
Next Earnings	25 lut 2026

Market Stats
By TradingEconomics
Market Cap	4.2B 13B
Previous open	521.28
Previous close	513.79

News Sentiment

By Acuity

50%

187 / 370 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 sty 2026, 22:18 UTC

Market Talk

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9 sty 2026, 21:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9 sty 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

9 sty 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 sty 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9 sty 2026, 21:43 UTC

Earnings

Acquisitions, Mergers, Takeovers

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9 sty 2026, 20:39 UTC

Market Talk

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9 sty 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9 sty 2026, 20:36 UTC

Acquisitions, Mergers, Takeovers

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9 sty 2026, 20:30 UTC

Market Talk

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9 sty 2026, 20:15 UTC

Market Talk

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9 sty 2026, 20:07 UTC

Market Talk

Global Equities Roundup: Market Talk

9 sty 2026, 20:07 UTC

Market Talk

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9 sty 2026, 19:58 UTC

Acquisitions, Mergers, Takeovers

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 sty 2026, 19:42 UTC

Market Talk

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9 sty 2026, 19:38 UTC

Acquisitions, Mergers, Takeovers

Wolters Kluwer Acquires StandardFusion >WTKWY

9 sty 2026, 19:31 UTC

Earnings

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9 sty 2026, 19:28 UTC

Earnings

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9 sty 2026, 18:30 UTC

Market Talk

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9 sty 2026, 18:23 UTC

Market Talk

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9 sty 2026, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

9 sty 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 sty 2026, 17:19 UTC

Market Talk

Energy Prices Not Seen Supporting More Drilling -- Market Talk

9 sty 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 sty 2026, 17:07 UTC

Market Talk

McDonald's Promotions Appear Successful -- Market Talk

9 sty 2026, 17:06 UTC

Market Talk

Oil Futures on Track for Weekly Gains -- Market Talk

9 sty 2026, 17:05 UTC

Earnings

Stocks Sail Past Jobs Data, Tariff Opinion Delay. Earnings Season Looms. -- Barrons.com

9 sty 2026, 16:57 UTC

Market Talk

Energy Activity Tumbles in 4Q, KC Fed Survey Finds -- Market Talk

9 sty 2026, 16:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 sty 2026, 16:46 UTC

Market Talk

Dollar Could Stay Steady For Now, More Likely to Fall Than Rise -- Market Talk

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

12.58% upside

12 Months Forecast

Average 626.22 USD 12.58%

High 900 USD

Low 527 USD

Based on 12 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

187 / 370 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.